Lineage Cell The Stock Price, News & Analysis

Lineage Cell Therapeutics (NYSE American: LCTX) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 after U.S. market close. Management will host a conference call and live webcast on November 6, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a business update.

Dial-in for the call from the U.S. and Canada is (888) 596-4144 (request “Lineage Cell Therapeutics Call”). A live webcast will be available in the Investors section of Lineage’s website. Webcast replay will be available on the website for 30 days, and a telephone replay is available through November 14, 2025 at (800) 770-2030 using conference ID 3958367.

Lineage Cell Therapeutics (NYSE American: LCTX) has launched a new islet cell transplant program targeting Type 1 Diabetes (T1D). The company's primary focus is addressing the manufacturing scale challenges in islet cell production, aiming to establish a dynamic culturing system that can support large-scale production.

CEO Brian M. Culley highlighted that while several islet cell programs have reached Phase 1 clinical trials, the industry faces significant challenges in manufacturing sufficient material for the addressable patient population. The company plans to leverage its GMP manufacturing capabilities to develop a production system capable of generating hundreds of millions of cells per patient.

The initiative will begin with testing their proprietary cell line, marking their third unique master cell bank at their in-house facility. Future plans include demonstrating system compatibility with hypo-immune cell lines for clinical T1D applications.

Lineage Cell Therapeutics (NYSE:LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological and ophthalmic conditions, has announced upcoming investor conference presentations.

CEO Brian M. Culley will present at two major healthcare conferences: the H.C. Wainwright Global Investment Conference on September 8, 2025, at 11:30am ET, and Baird's Global Healthcare Conference on September 9, 2025, at 12:50pm ET. A replay of the H.C. Wainwright presentation will be available on the company's website after the event.

Lineage Cell Therapeutics (NYSE American: LCTX) has entered into a significant research collaboration with William Demant Invest A/S (WDI) to develop ReSonance™ (ANP1), a novel cell therapy for hearing loss. The partnership includes up to $12 million in funding from WDI over a three-year term to advance preclinical development.

The collaboration will combine Lineage's cell manufacturing expertise with hearing loss research from Eriksholm Research Centre. The development activities will cover cell manufacturing, proof-of-concept studies, delivery development, and regulatory strategy to support potential IND/CTA filing.

ReSonance represents Lineage's first internally-developed cell transplant program, targeting auditory nerve cell restoration for the 2.5 billion people expected to experience hearing loss by 2025. The therapy aims to treat auditory neuropathy by replacing damaged auditory nerve cells to restore hearing and potentially enhance cochlear implant effectiveness.

Lineage Cell Therapeutics (NYSE:LCTX) reported Q2 2025 financial results and significant clinical progress. The company highlighted positive 36-month results from the OpRegen Phase 1/2a trial, showing sustained benefits in treating geographic atrophy, with treated patients demonstrating a mean improvement of +6.2 letters in vision acuity.

Key financial metrics include $42.3 million in cash reserves supporting operations into Q1 2027, revenues of $2.8 million (up from $1.4M YoY), and a net loss of $30.5 million. The company achieved manufacturing milestones and treated its first chronic patient in the OPC1 spinal cord injury program.

The quarter was marked by a $14.8 million impairment charge related to the VAC platform and increased warrant liability expenses due to share price appreciation.

Lineage Cell Therapeutics (NYSE American: LCTX), a clinical-stage biotechnology company focused on allogeneic cell therapies for neurological conditions, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after U.S. market close.

The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Investors can access the call by dialing (800) 715-9871 from the U.S. and Canada. A webcast replay will be available for 30 days, and a telephone replay through August 19, 2025, can be accessed using conference ID 7788342.

Lineage Cell Therapeutics (NYSE:LCTX) has announced a significant milestone in its DOSED clinical study with the first-ever treatment of a chronic spinal cord injury patient using OPC1 cells and a new parenchymal spinal delivery system at UC San Diego Health.

The study will evaluate both subacute (21-42 days post-injury) and chronic (1-5 years post-injury) spinal cord injury patients. The first patient, with a complete SCI injury (AIS grade A), successfully received a one-time injection of 10 million OPC1 cells. OPC1, an allogeneic stem cell-derived cell transplant, aims to restore or enhance functional activity in SCI patients by replacing damaged cells.

The treatment builds on extensive safety data from two previous clinical trials, including a 5-patient Phase 1 trial with 13+ years of follow-up and a 25-patient Phase 1/2a trial with 7+ years of monitoring, both showing no unexpected serious adverse events.

Lineage Cell Therapeutics reported promising 36-month results for OpRegen (RG6501) cell therapy in treating Geographic Atrophy (GA) secondary to age-related macular degeneration. The Phase 1/2a clinical study showed significant improvements, particularly in patients with extensive OpRegen coverage. Key findings include mean vision gains of +9 letters in patients with extensive coverage, sustained improvements in retinal structure, and persistent benefits up to 3 years post-treatment. Notably, patients with extensive OpRegen coverage showed mean BCVA improvement of +9.0 ETDRS letters at 3 years, compared to +7.4 letters at 24 months. The therapy demonstrated potential to counteract RPE cell loss and improve retinal structure, with treated eyes maintaining positive changes while untreated eyes showed deterioration. A Phase 2a GAlette study is currently enrolling patients to evaluate optimal delivery methods.

Lineage Cell Therapeutics (NYSE: LCTX) has announced updates for its 3rd Annual Spinal Cord Injury Investor Symposium, scheduled for June 27, 2025, as a fully virtual event. The symposium will feature an impressive lineup of thought leaders, including medical professionals, researchers, and individuals with lived spinal cord injury experience. Notable presenters include Dr. Armin Curt from Balgrist University Hospital, Dr. Richard Fessler from RUSH University Medical Center, and various corporate participants such as NervGen Pharma, NovaGo Therapeutics, and ONWARD Medical. The event will cover crucial topics including SCI treatment approaches, drug development, healthcare disparities, and clinical endpoints. The symposium is free to attend and aims to foster collaborative discussions on advancing spinal cord injury treatments.